SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 410 participants.
Also called NCT06955260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 410 participants
- Registry
-
NCT06955260
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT06955260. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
- Acronym
- EMPA-HEART-3
- Condition
- Congenital Heart Disease
- Intervention (Drug)
- Empagliflozin 10 mg
- Intervention (Other)
- Placebo
- Lead sponsor
- Subodh Verma
- Collaborator
- Boehringer Ingelheim
- Collaborator
- Applied Health Research Centre
Record details
- Record id
cardio:ct-nct06955260- Content hash
25bbaaefcd9a22dc21a5f1c014b6aa86e33b67c7db089750a0171420054a9a54